AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL
June 6, 2016 9:03 AM EDTAbbVie (NYSE: ABBV) announced longer-term follow-up results from Phase 3 studies of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115) trials, which showed IMBRUVICA was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-naïve; abstract 7520). Other data include first-ever presentation of longer-term follow-up data from the HELIOS (CLL3001) trial showing... More
Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'
June 6, 2016 7:36 AM EDT(Updated - June 6, 2016 9:21 AM EDT)
Cowen downgraded Abbvie (NYSE: ABBV) from Outperform to Market Perform with a price target of $70 (prior $77). Analyst Steve Scala called Rova-T data at ASCO "underwhelming." Overall, he sees opportunities as balanced.
"Last Fridays analyst meeting was solid, but provided limited news to bolster visibility on the L-T outlook. Rova-T data at ASCO was underwhelming and does not enhance confidence in capital deployment post the $5.8B Stemcentrx acquisition. ABBV stock has been a good performer, despite the recent Humira IPR, offering opportunity to lock in profits. We believe... More
AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment
June 6, 2016 6:26 AM EDTAbbVie (NYSE: ABBV) announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in... More
